These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38952609)
1. Immunophenotypic Profile and Measurable Residual Disease Monitoring in Multiple Myeloma: A Prospective Study From a Tertiary Care Centre in Southern India. Sathya P; Kayal S; Hamide A; Kar R Cureus; 2024 Jun; 16(6):e61504. PubMed ID: 38952609 [TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534 [TBL] [Abstract][Full Text] [Related]
3. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data. Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387 [TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry. Gupta R; Gupta P; Rahman K; Biswas S; Chandra D; Singh MK; Sarkar MK; Gupta A; Nityanand S Indian J Hematol Blood Transfus; 2022 Jul; 38(3):473-480. PubMed ID: 35747566 [TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients. Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071 [TBL] [Abstract][Full Text] [Related]
6. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels]. Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086 [No Abstract] [Full Text] [Related]
7. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315 [TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry. Schouweiler KE; Karandikar NJ; Holman CJ Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731 [TBL] [Abstract][Full Text] [Related]
10. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Jeong TD; Park CJ; Shim H; Jang S; Chi HS; Yoon DH; Kim DY; Lee JH; Lee JH; Suh C; Lee KH Korean J Hematol; 2012 Dec; 47(4):260-6. PubMed ID: 23320004 [TBL] [Abstract][Full Text] [Related]
11. [Impact of minimal residual disease detection after treatment of multiple myeloma]. Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098 [TBL] [Abstract][Full Text] [Related]
12. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates. Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142 [TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic Profile of Multiple Myeloma: A Tertiary Care Centre Experience. Rath A; Panda T; Dass J; Seth T; Mahapatra M; Tyagi S J Lab Physicians; 2023 Sep; 15(3):392-398. PubMed ID: 37564229 [No Abstract] [Full Text] [Related]
14. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry. Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180 [TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235 [TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814 [TBL] [Abstract][Full Text] [Related]
17. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis]. Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777 [TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients. Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331 [TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070 [TBL] [Abstract][Full Text] [Related]
20. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. Limvorapitak W; Srisum-Ang T; Chimres C; Warnnissorn N; Kanitsap N Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e27-37. PubMed ID: 26796980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]